Deutsche Bank analyst George Hill lowered the firm’s price target on Agilon Health (AGL) to $2 from $4 and keeps a Hold rating on the shares post the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health downgraded to Market Perform from Outperform at William Blair
- Agilon Health Reports Growth Amidst Financial Challenges
- Agilon Health Reports Revenue Rise Despite Net Loss
- Agilon Health reports Q3 EPS (29c), consensus (11c)
- Agilon Health cuts FY24 adjusted EBITDA to (155M)-(135M) from (60M)-(15)